Helex

Developing gene therapies for genetic kidney disease.

description

Helex has developed a proprietary lipid nanoparticle (LNP) delivery system that delivers gene-editing therapies directly to kidney cells, solving one of gene therapy's toughest challenges. Their lead program targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic kidney disorder affecting 12 million people worldwide with no curative treatment available.

founders

Poulami Chaudhuri

Rohini Kalvakuntla

Anirudh Nishtala

founded

2021

year of investment

Oct 2025

"

why we invested

ADPKD represents a significant unmet medical need, with current treatments limited to symptom management and not effective for all patients. Helex’s first-in-class mechanism of action has the potential to be a curative therapy and positions the company to build a differentiated pipeline of therapies for genetic kidney diseases.

read full article

"

Latest on

Helex

October 30, 2025

Helex Bio: Transforming treatment of renal genetic diseases

More from the

folio

Alternative protein using precision fermentation

Life Sciences

Materials

AI chatbot providing accessible mental health therapy.

AI assistant to streamline operations for small businesses

Exited